Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06624371 · ClinicalTrials.gov registry record · Phase 1

Atovaquone Combined With Radiation in Children With Malignant Brain Tumors

A Phase 1 study of High Grade Glioma and Medulloblastoma, sponsored by Emory University.

Recruiting
Registry status
Phase 1
Development phase
18
Enrollment target
2
Study locations

NCT06624371 is a Phase 1 study of High Grade Glioma and Medulloblastoma that is actively recruiting participants, run by Emory University. The registered enrollment target is 18 participants, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (72% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06624371, a Phase 1 study of High Grade Glioma and Medulloblastoma, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
Phase 1
Development phase
18 participants
Enrollment target
2
Study locations

Study Summary

The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade glioma/diffuse midline glioma/diffuse intrinsic pontine glioma (pHGG/DMG/DIPG). The secondary aim is to assess the safety and tolerability of longer-term atovaquone treatment for pediatric patients with relapsed or progressed pHGG/DMG/DIPG and medulloblastoma (MB) or pHGG/DMG/DIPG after completion of RT and before progression.

Conditions Studied

High Grade Glioma Medulloblastoma Diffuse Intrinsic Pontine Glioma Diffuse Midline Glioma, H3 K27M-Mutant

Interventions

  • RADIATION Radiation Therapy
  • DRUG Atovaquone

Study Locations (2)

Georgia

  • Arthur M Blank Hospital - Atlanta
  • Children's Healthcare of Atlanta: Scottish Rite - Atlanta

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2025-03-28
Est. Completion 2027-10
Phase Phase 1

Sponsor

Emory University

1,208 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06624371

The ClinicalTrials.gov registry entry for NCT06624371 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (72% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with High Grade Glioma appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.

NCT06624371 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT06624371 about?

NCT06624371 is a clinical study titled "Atovaquone Combined With Radiation in Children With Malignant Brain Tumors". The goal of this interventional study is to Assess the safety and tolerability of atovaquone in combination with standard radiation therapy (RT) for the treatment of pediatric patients with newly diagnosed pediatric high-grade glioma/diffuse midline glioma/diffuse intrinsic pontine glioma (pHGG/DMG/...

What is the current status of trial NCT06624371?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2025-03-28. Estimated completion is 2027-10.

What conditions does trial NCT06624371 study?

This clinical trial studies the following conditions: High Grade Glioma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant.

What interventions are being tested in trial NCT06624371?

The interventions under investigation include: Radiation Therapy (RADIATION), Atovaquone (DRUG).

Who is sponsoring clinical trial NCT06624371?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06624371 being conducted?

This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for High Grade Glioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

High Grade Glioma

All registered trials for this condition

Medulloblastoma

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.